Bicycle Therapeutics plc
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsBicycle Therapeutics is a clinical-stage biopharmaceutical company developing synthetic bicyclic peptide-based oncology therapeutics, including drug conjugates and radioconjugates.
What they do
Bicycle Therapeutics develops Bicycle molecules, fully synthetic short peptides constrained into two loops, which combine biologic-like affinity with small-molecule manufacturing and pharmacokinetics. Its internal programs focus on oncology, including Bicycle Drug Conjugates (BDCs) and Bicycle Radioconjugates (BRCs). The company uses a proprietary phage display platform to screen quintillions of potential molecules. Lead candidates include nuzefatide pevedotin (EphA2-targeting BDC) and BT1702 (MT1-MMP-targeting BRC).
Revenue drivers
- Collaboration revenue — Revenue primarily comes from collaboration agreements; annual revenue was $72.6M in 2025, up from $35.3M in 2024, but recent quarterly revenue dropped to $0.6M in Q2 2026.
- Nuzefatide pevedotin (BT5528) — EphA2-targeting BDC in Phase I/II for advanced solid tumors and Phase II for recurrent metastatic pancreatic cancer; first patient dosed in April 2026.
- Zelenectide pevedotin — Nectin-4-targeting BDC; Phase II/III Duravelo-2 trial in metastatic urothelial cancer, but deprioritized for internal development after March 2026 reprioritization.
- BT1702 and Bicycle Imaging Agents (BIAs) — BT1702 (MT1-MMP-targeting BRC) in IND-enabling; BIAs used for target validation and triage; human imaging data presented at AACR 2026.
Recent performance
In Q2 2026, Bicycle reported revenue of $0.6M and cash and cash equivalents of $510.1M at June 30, 2026. The company reported a net loss of $219.0M for 2025, with operating cash flow of -$249.7M. Recent quarterly revenue declined sharply from $48.0M in Q4 2025 to $0.9M in Q1 2026 and $0.6M in Q2 2026. The company maintains an expected cash runway into 2030.
Strategy
Management announced a strategic reprioritization in March 2026 to focus on next-generation therapeutics, including nuzefatide pevedotin and BRC molecules. The Duravelo-2 registrational trial for zelenectide pevedotin was converted to a randomized Phase II trial and the program was deprioritized for internal development. The company is advancing BT1702 toward a Phase 1 trial expected to begin in 2027. BIA molecules are used to derisk novel targets and triage cancer indications. Management emphasizes financial discipline and capital allocation to extend cash runway.
Risks
- Clinical-stage and loss-making — The company has a history of significant operating losses and expects increasing losses; it may never achieve profitability.
- Dependence on key candidates — Substantially dependent on the success of nuzefatide pevedotin and BT1702, which may fail in clinical trials or regulatory approval.
- Need for additional funding — Although cash runway extends into 2030, the company may need substantial additional funding and could face dilution or relinquish rights.
- Regulatory and development risks — Early-stage product candidates may not complete clinical trials or receive regulatory approval, and any delay could harm the business.
Outlook
Management expects to begin the Phase 1 trial for BT1702 in 2027, with IND-enabling activities ongoing. The Phase 2 trial for nuzefatide in recurrent pancreatic cancer is actively enrolling, with first patient dosed in April 2026. Additional human imaging data for EphA2 BIA in PDAC were presented at AACR 2026, supporting target validation. The company plans to continue advancing its radioligand pipeline and next-generation Bicycle conjugates.